ak104

Key facts

Mechanism of action

Cytotoxic T-lymphocyte protein 4 inhibitor

Primary target: Cytotoxic T-lymphocyte protein 4

Approval history

1. AK104 Phase 2 · Akeso · Advanced Malignant Tumors
2. AK104 Phase 2 · Chinese Academy of · Resectable Non-small Cell Lung Cancer
3. Cadonilimab Phase 2 · First People's Hospital · Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
4. L2023-K003-002 Phase 2 · First People's Hospital · Esophageal Squamous Cell Carcinoma
5. Nab-paclitaxel Combined With Cadonilimab (AK104) Phase 2 · Chinese Academy of · Gastric Cancer
6. cadonilimab combined +paclitaxel (albumin-bound) Phase 2 · Chinese Academy of · Gastric Adenocarcinoma
7. Cadonilimab Unknown · First People's Hospital · Locally Advanced Esophageal Squamous Cell Carcinoma

1. ipilimumab Antineoplastic and immunomodulating agents (L01)
2. tremelimumab-actl Cytotoxic T-lymphocyte protein 4 inhibitor
3. tremelimumab Antineoplastic and immunomodulating agents (L01)
4. cadonilimab Cytotoxic T-lymphocyte protein 4 inhibitor
5. kn046 Cytotoxic T-lymphocyte protein 4 inhibitor

Frequently asked questions